Therapeutic Implications of Targeting Energy Metabolism in Breast Cancer
Open Access
- 3 February 2013
- journal article
- review article
- Published by Hindawi Limited in PPAR Research
- Vol. 2013, 1-11
Abstract
PPARs are ligand activated transcription factors. PPARγagonists have been reported as a new and potentially efficacious treatment of inflammation, diabetes, obesity, cancer, AD, and schizophrenia. Since cancer cells show dysregulation of glycolysis they are potentially manageable through changes in metabolic environment. Interestingly, several of the genes involved in maintaining the metabolic environment and the central energy generation pathway are regulated or predicted to be regulated by PPARγ. The use of synthetic PPARγligands as drugs and their recent withdrawal/restricted usage highlight the lack of understanding of the molecular basis of these drugs, their off-target effects, and their network. These data further underscores the complexity of nuclear receptor signalling mechanisms. This paper will discuss the function and role of PPARγin energy metabolism and cancer biology in general and its emergence as a promising therapeutic target in breast cancer.Keywords
This publication has 112 references indexed in Scilit:
- Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not AnticipateCancer Cell, 2012
- SIRT1 is regulated by a PPARγ–SIRT1 negative feedback loop associated with senescenceNucleic Acids Research, 2010
- HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancerNature, 2009
- Cellular stress and RNA splicingTrends in Biochemical Sciences, 2009
- Hexokinase-2 bound to mitochondria: Cancer's stygian link to the “Warburg effect” and a pivotal target for effective therapySeminars in Cancer Biology, 2009
- Cancer Cell Metabolism: Warburg and BeyondCell, 2008
- New roles for pyruvate kinase M2: working out the Warburg effectTrends in Biochemical Sciences, 2008
- Energy balance, insulin resistance biomarkers, and breast cancer riskCancer Detection Prevention, 2007
- Hexokinase II: Cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondriaOncogene, 2006
- ROS stress in cancer cells and therapeutic implicationsDrug Resistance Updates, 2004